These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23614733)

  • 1. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
    J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease.
    Boswood A; Dukes-McEwan J; Loureiro J; James RA; Martin M; Stafford-Johnson M; Smith P; Little C; Attree S
    J Small Anim Pract; 2008 Jan; 49(1):26-32. PubMed ID: 18005104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure.
    Kanno N; Hori Y; Hidaka Y; Chikazawa S; Kanai K; Hoshi F; Itoh N
    J Vet Med Sci; 2016 May; 78(4):535-42. PubMed ID: 26607133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
    Serres F; Pouchelon JL; Poujol L; Lefebvre HP; Trumel C; Daste T; Sampedrano CC; Gouni V; Tissier R; Hawa G; Chetboul V
    J Vet Cardiol; 2009 Dec; 11(2):103-21. PubMed ID: 19850546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NT-proBNP, NT-proANP and cTnI concentrations in dogs with pre-capillary pulmonary hypertension.
    Kellihan HB; Mackie BA; Stepien RL
    J Vet Cardiol; 2011 Sep; 13(3):171-82. PubMed ID: 21835711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of natriuretic peptides in dogs with mitral valve disease.
    Tarnow I; Olsen LH; Kvart C; Hoglund K; Moesgaard SG; Kamstrup TS; Pedersen HD; Häggström J
    Vet J; 2009 May; 180(2):195-201. PubMed ID: 18675567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and its association with oxidative stress in dogs with heart failure.
    Nemec Svete A; Verk B; Čebulj-Kadunc N; Salobir J; Rezar V; Domanjko Petrič A
    BMC Vet Res; 2021 Apr; 17(1):176. PubMed ID: 33902566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease.
    Fine DM; DeClue AE; Reinero CR
    J Am Vet Med Assoc; 2008 Jun; 232(11):1674-9. PubMed ID: 18518809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity.
    Oyama MA; Fox PR; Rush JE; Rozanski EA; Lesser M
    J Am Vet Med Assoc; 2008 May; 232(10):1496-503. PubMed ID: 18479239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease.
    Hezzell MJ; Boswood A; Chang YM; Moonarmart W; Souttar K; Elliott J
    J Vet Intern Med; 2012; 26(2):302-11. PubMed ID: 22369312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.